SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for diabetes, have revealed remarkable cardiovascular and renal protective properties, mitigating the risk of kidney replacement therapy and mortality, even in advanced CKD stages [6,77].